Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease.

by K D Ramaiah, Eric A Ottesen
Published 2014-11-01

The global programme to eliminate lymphatic filariasis: health impact after 8 years.

by Eric A Ottesen, Pamela J Hooper, Mark Bradley, Gautam Biswas
Published 2008-10-01

Antibody to the filarial antigen Wb123 reflects reduced transmission and decreased exposure in children born following single mass drug administration (MDA).

by Cathy Steel, Joseph Kubofcik, Eric A Ottesen, Thomas B Nutman
Published 2012-01-01

Assessing progress in reducing the at-risk population after 13 years of the global programme to eliminate lymphatic filariasis.

by Pamela J Hooper, Brian K Chu, Alexei Mikhailov, Eric A Ottesen, Mark Bradley
Published 2014-11-01

Global programme to eliminate lymphatic filariasis: the processes underlying programme success.

by Kazuyo Ichimori, Jonathan D King, Dirk Engels, Aya Yajima, Alexei Mikhailov, Patrick Lammie, Eric A Ottesen
Published 2014-12-01

The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000-2007).

by Brian K Chu, Pamela J Hooper, Mark H Bradley, Deborah A McFarland, Eric A Ottesen
Published 2010-06-01

Predictive vs. empiric assessment of schistosomiasis: implications for treatment projections in Ghana.

by Achille Kabore, Nana-Kwadwo Biritwum, Philip W Downs, Ricardo J Soares Magalhaes, Yaobi Zhang, Eric A Ottesen
Published 2013-01-01

National mass drug administration costs for lymphatic filariasis elimination.

by Ann S Goldman, Victoria H Guisinger, Moses Aikins, Maria Lourdes E Amarillo, Vicente Y Belizario, Bertha Garshong, John Gyapong, Conrad Kabali, Hussein A Kamal, Sanjat Kanjilal, Dominique Kyelem, Jefrey Lizardo, Mwele Malecela, Godfrey Mubyazi, P Abdoulaye Nitièma, Reda M R Ramzy, Thomas G Streit, Aaron Wallace, Molly A Brady, Richard Rheingans, Eric A Ottesen, Anne C Haddix
Published 2007-01-01

A multicenter evaluation of diagnostic tools to define endpoints for programs to eliminate bancroftian filariasis.

by Katherine Gass, Madsen V E Beau de Rochars, Daniel Boakye, Mark Bradley, Peter U Fischer, John Gyapong, Makoto Itoh, Nese Ituaso-Conway, Hayley Joseph, Dominique Kyelem, Sandra J Laney, Anne-Marie Legrand, Tilaka S Liyanage, Wayne Melrose, Khalfan Mohammed, Nils Pilotte, Eric A Ottesen, Catherine Plichart, Kapa Ramaiah, Ramakrishna U Rao, Jeffrey Talbot, Gary J Weil, Steven A Williams, Kimberly Y Won, Patrick Lammie
Published 2012-01-01

Transmission assessment surveys (TAS) to define endpoints for lymphatic filariasis mass drug administration: a multicenter evaluation.

by Brian K Chu, Michael Deming, Nana-Kwadwo Biritwum, Windtaré R Bougma, Améyo M Dorkenoo, Maged El-Setouhy, Peter U Fischer, Katherine Gass, Manuel Gonzalez de Peña, Leda Mercado-Hernandez, Dominique Kyelem, Patrick J Lammie, Rebecca M Flueckiger, Upendo J Mwingira, Rahmah Noordin, Irene Offei Owusu, Eric A Ottesen, Alexandre Pavluck, Nils Pilotte, Ramakrishna U Rao, Dilhani Samarasekera, Mark A Schmaedick, Sunil Settinayake, Paul E Simonsen, Taniawati Supali, Fasihah Taleo, Melissa Torres, Gary J Weil, Kimberly Y Won
Published 2013-01-01